Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial-Reference-Cited by-同舟云学术

Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial

Published:2017-07 Issue:7 Volume:18 Page:863-873
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Davies Michael A,Saiag Philippe,Robert Caroline,Grob Jean-Jacques,Flaherty Keith T,Arance Ana,Chiarion-Sileni Vanna,Thomas Luc,Lesimple Thierry,Mortier Laurent,Moschos Stergios J,Hogg David,Márquez-Rodas Iván,Del Vecchio Michele,Lebbé Céleste,Meyer Nicolas,Zhang Ying,Huang Yingjie,Mookerjee Bijoyesh,Long Georgina V

Publisher

Elsevier BV

Subject

Oncology

Reference28 articles.

1. Melanoma central nervous system metastases: current approaches, challenges, and opportunities;Cohen;Pigment Cell Melanoma Res,2016

2. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma;Sampson;J Neurosurg,1998

3. Multidisciplinary approach to brain metastasis from melanoma: the emerging role of systemic therapies;Long;Am Soc Clin Oncol Educ Book,2013

4. Prognostic factors for survival in melanoma patients with brain metastases;Davies;Cancer,2011

5. Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features;Raizer;Neuro Oncol,2008

Cited by 593 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Network-based analysis of heterogeneous patient-matched brain and extracranial melanoma metastasis pairs reveals three homogeneous subgroups;Computational and Structural Biotechnology Journal;2024-12

2. Melanoma Brain Metastasis;Hematology/Oncology Clinics of North America;2024-10

3. Progress in Immune Checkpoint Inhibitor for Melanoma Therapy;Hematology/Oncology Clinics of North America;2024-10

4. Real-Life Outcomes of Adjuvant Targeted Therapy and Anti-PD1 Agents in Stage III/IV Resected Melanoma;Cancers;2024-09-06

5. “Symptomatic” melanoma brain metastases: A call for clear definitions and adoption of standardized tools;European Journal of Cancer;2024-09